Abstract:While opening new frontiers for the cure of malignant and non-malignant diseases, the increasing use of cell therapy poses also several new challenges related to the safety of a living drug. The most effective and consolidated cell therapy approach is allogeneic hematopoietic stem cell transplantation (HSCT), the only cure for several patients with high-risk hematological malignancies. The potential of allogeneic HSCT is strictly dependent on the donor immune system, particularly on alloreactive T lymphocytes, that promote the beneficial graft-versus-tumor effect (GvT), but may also trigger the detrimental graft-versus-host-disease (GvHD). Gene transfer technologies allow to manipulate donor T-cells to enforce GvT and foster immune reconstitution, while avoiding or controlling GvHD. The suicide gene approach is based on the transfer of a suicide gene into donor lymphocytes, for a safe infusion of a wide T-cell repertoire, that might be selectively controlled in vivo in case of GvHD. The herpes simplex virus thymidine kinase (HSV-TK) is the suicide gene most extensively tested in humans. Expression of HSV-TK in donor lymphocytes confers lethal sensitivity to the anti-herpes drug, ganciclovir. Progressive improvements in suicide genes, vector technology and transduction protocols have allowed to overcome the toxicity of GvHD while preserving the antitumor efficacy of allogeneic HSCT. Several phase I-II clinical trials in the last 20 years document the safety and the efficacy of HSV-TK approach, able to maintain its clear value over the last decades, in the rapidly progressing horizon of cancer cellular therapy.

Research status and prospect of suicide gene therapy for malignant tumor

Research and Progress on Suicide Gene Therapy for Pancreatic Tumor

Current Progress in Suicide Gene Therapy for Cancer

Advancement and prospects of tumor gene therapy

Enhancements on HSV-tk/GCV Cancer Suicide Gene Therapy System

Advance in Gene Therapy of Tumors

Combined Therapy of Suicide Gene and Cytokine Gene for Cancer

Section Review—Oncologic, Endocrine & Metabolic: Gene Therapy Strategies for Cancer

Present Status of Gene Therapy for Lung Cancer

Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy

Research Development of Gene Therapy for Glioma

Research Development of Cancer Gene Therapy

Mechanism Research of HSV-TK/GCV System on Tumor Gene Therapy

Application and Challenge of Gene Therapy for Cancer

Progress of Hypoxia/radiation Dual-sensitive Promoter Controlling Suicide Gene Expression in Radiotherapy

Cancer biotherapy: review and prospect

[Experimental study of tissue-specific suicide gene therapy for lung adenocarcinoma].

In vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line

Improving the safety of cell therapy with the TK-suicide gene

Advancements in p53-Based Anti-Tumor Gene Therapy Research

A Study on the Immune Response of Mice with Gastric Cancer Induced by Gene Therapy